**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 90593

**Manuscript Type:** EDITORIAL

**Management of autoimmune hepatitis induced by hepatitis delta virus**

Gigi E *et al*. Management of AIH induced by HDV

Eleni Gigi, Vasileios Lagopoulos, Aris Liakos

**Eleni Gigi,** Hepatology Unit, The Second Internal Medicine Department, Aristotle University Medical School, Hippokrateio General Hospital, Thessaloniki 54642, Greece

**Vasileios Lagopoulos,** Department of Surgical, AHEPA General Hospital of Thessaloniki, Thessaloniki 54636, Greece

**Aris Liakos,** Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Hippokratio General Hospital, Aristotle University Thessaloniki, Thessaloniki 54642, Greece

**Author contributions:** Gigi E conceived the title, designed, and wrote the manuscript, and performed the final revision; Lagopoulos V contributed in the writing and the revision of the manuscript; Liakos A contributed in the writing and the revision of the manuscript.

**Corresponding author: Eleni Gigi, MD, PhD, Academic Research, Assistant Professor,** Hepatology Unit, The Second Internal Medicine Department, Aristotle University Medical School, Hippokrateio General Hospital, 49 Konstantinoupoleos, Thessaloniki 54642, Greece. elengigi@auth.gr

**Received:** December 7, 2023

**Revised:** January 2, 2024

**Accepted:** January 30, 2024

**Published online:** February 28, 2024

**Abstract**

Approximately 12-72 million people worldwide are co-infected with hepatitis B virus (HBV) and hepatitis delta virus (HDV). This concurrent infection can lead to several severe outcomes with hepatic disease, such as cirrhosis, fulminant hepatitis, and hepatocellular carcinoma, being the most common. Over the past few decades, a correlation between viral hepatitis and autoimmune diseases has been reported. Furthermore, autoantibodies have been detected in the serum of patients co-infected with HBV/HDV, and autoimmune features have been reported. However, to date, very few cases of clinically significant autoimmune hepatitis (AIH) have been reported in patients with HDV infection, mainly in those who have received treatment with pegylated interferon. Interestingly, there are some patients with HBV infection and AIH in whom HDV infection is unearthed after receiving treatment with immunosuppressants. Consequently, several questions remain unanswered with the challenge to distinguish whether it is autoimmune or “autoimmune-like” hepatitis being the most crucial. Second, it remains uncertain whether autoimmunity is induced by HBV or delta virus. Finally, we investigated whether the cause of AIH lies in the previous treatment of HDV with pegylated interferon. These pressing issues should be elucidated to clarify whether new antiviral treatments for HDV, such as Bulevirtide or immunosuppressive drugs, are more appropriate for the management of patients with HDV and AIH.

**Key Words:** Autoimmune hepatitis; Hepatitis delta virus; Bulevirtide; Prednisolone

**©The** **Author(s) 2024.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Gigi E, Lagopoulos V, Liakos A. Management of autoimmune hepatitis induced by hepatitis delta virus. *World J Gastroenterol* 2024; 30(8): 799-805

**URL**: https://www.wjgnet.com/1007-9327/full/v30/i8/799.htm

**DOI**: https://dx.doi.org/10.3748/wjg.v30.i8.799

**Core Tip:** There are some pressing issues that should be elucidated in order to clarify whether new antiviral treatments for hepatitis delta virus (HDV), such as Bulevirtide, or immunosuppressive drugs, are more appropriate for the management of patients with HDV and autoimmune hepatitis (AIH). Firstly, several questions remain unanswered with the challenge to distinguish whether it is autoimmune or “autoimmune-like” hepatitis being the most crucial. Secondly, it yet remains uncertain whether autoimmunity is induced by the hepatitis B virus or the Delta virus. Finally, if the cause of AIH lies on the previous treatment of HDV with pegylated interferon.

**INTRODUCTION**

Hepatitis delta virus (HDV) was first recognized back in late 1970s as new antigen in the serum of hepatitis B surface antigen (HBsAg) positive patients, termed δ, whilst subsequent clinical trials in chimpanzees proved its existence in 1980[1]. HDV, the smallest pathogenic virus in human virology, consists of a circular single-stranded negative RNA genome and two types of hepatitis delta antigens, small and large (L-HDAg and S-HDAg, respectively), enveloped by HBsAg. Eight HDV genotypes with various geographical distributions were identified. With HBsAg on its surface, HDV enters hepatocytes *via* sodium taurocholate co-transporting polypeptide (NTCP). Genomic HDVRNA then moves to the nucleus, where it replicates *via* a rolling-circle mechanism. During replication, two species of HDAg (L-HDAg and S-HDAg) are formed: S-HDAg triggers further replication of the virus, while L-HDAg inhibits replication and promotes virion packaging through farnesylation[2]. Many clinical studies have shown that HDV infection most often causes progressive liver disease more rapidly than other viral hepatitis, leading to liver cirrhosis in 70% of cases within 5 to 10 years[3]. Furthermore, HDV is independently associated with an increased risk of hepatocellular carcinoma (HCC) than hepatitis B virus (HBV) monoinfection[4] and has been associated with the development of autoimmune hepatitis (AIH), as in the serum of HBV/HDV co-infected patients, positive autoantibodies have been detected, and autoimmune features have been reported[5].

**AIH**

AIH is an immune-mediated inflammatory disease of the liver, characterized by circulating autoantibodies, increased concentrations of immunoglobulin G (IgG), and specific histological features[6]. The origin of the disease is presumed to be a loss of immunologic tolerance against hepatocytes induced by environmental factors, but also triggered by specific viral infections (Hepatitis B, C, E, A, and Epstein-Barr), genetic factors, exposure to certain drugs (*e.g.*, nitrofurantoin, minocycline), and some individual risk factors (*e.g.*, sex, age, hormonal status, and comorbidities)[7]. The clinical presentation can be extremely heterogeneous, ranging from asymptomatic disease to fulminant hepatitis, leading to acute liver failure, with the acute onset of AIH being the most frequent pattern worldwide[7]. AIH can be classified into two types according to the pattern of autoantibodies detected. AIH type 1 is characterized by the presence of antinuclear antibodies (ANA) and/or smooth muscle autoantibodies (SMA) and sometimes perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA). AIH type 2 is characterized by the presence of antibodies against kidney microsome-1 (anti-LKM1), anti-LKM 3, and/or liver cytosolic type 1[8].

***Diagnosis of AIH***

AIH is diagnosed based on clinical, serological, and histological data. Clinical data may include nonspecific symptoms such as fatigue, arthralgia, malaise, amenorrhea, or symptoms and signs of hepatic cirrhosis. Laboratory findings included high concentrations of aminotransferases, detection of the specific autoantibodies mentioned above, and hypergammaglobulinemia (IgG). The histological features of AIH are not typical, as they are similar to those observed in active chronic hepatitis, mainly portal lymphoplasmacytic inflammation with interfacial activity and variable degrees of lobular hepatitis, emperipolesis, and hepatocyte rosettes[7,8]. Although imaging studies have a limited role in the diagnosis of AIH, they are useful for the assessment of liver complications, progression to cirrhosis, and screening for HCC. Currently, imaging is used worldwide to evaluate liver disease progression in patients with AIH. Ultrasound elastography is the most useful noninvasive tool for monitoring patients treated for AIH[9].

***Treatment of AIH***

Once AIH is diagnosed, treatment is initiated. In most cases, untreated AIH may lead to liver failure and death within five years of onset, whereas properly treated patients have an excellent prognosis. The aim of treatment for AIH is to achieve and maintain disease remission and symptom resolution, thus halting or even reversing liver damage and fibrosis. However, treatment may cause serious side effects and significant impairment of quality of life. Therefore, an individualized approach is required, taking into consideration not only disease-related factors (inflammatory activity and stage of fibrosis), but also patient characteristics and values (such as life expectancy, comorbidities, living conditions, and patients’ personal preferences).

Steroids remain the cornerstone of AIH remission, which is defined as a full biochemical response (normalization of both transaminases and IgG concentrations). The recommended initial dosage varies depending mostly on the profile of the patient and/or the stage of AIH. Starting with a dose of 0.5 mg/kg/d seems to have comparable efficacy to the widely accepted initial dose of 1.0 mg/kg/d, with a slightly slower response rate but fewer side effects; thus, doses higher than 0.5 mg/kg/d of prednisolone should be reserved only for severe acute disease. The response to steroid therapy is usually rapid, as transaminase concentrations start falling within a week, while IgG levels subside more slowly due to their prolonged half-life. Steroid tapering should be started as soon as signs of a biochemical response are observed, usually in steps of 5 mg every week, down to 10 mg of prednisolone per day, until a complete biochemical response is achieved. Budesonide can be used as an alternative to prednisolone, showing a slightly slower response and fewer side effects[10,11].

Although steroids are regarded as first-line treatment, azathioprine is used for maintenance as a corticosteroid-sparing regimen. Azathioprine can induce sustained remission while reducing the side effects of steroid therapy. Therefore, azathioprine should be administered as early as possible following the initial response, usually 7 d to 14 d after steroid treatment. Azathioprine should also be started at a low dose to avoid intolerance; the recommended dose is 50 mg/d, with careful monitoring of side effects, including full blood counts taken every 1 wk to 2 wk. If no side effect is observed, the dose of azathioprine should then be increased to 1-2 mg/kg/d. Once a complete biochemical response is achieved, immunosuppressive therapy should be titrated to the level required to retain the full response, with steroids preferably tapered out completely. In case of relapse during tapering, steroids should be reintroduced at slightly higher dose[12,13]. For patients who cannot tolerate azathioprine, mycophenolate mofetil (MMF) can be used as an alternative agent at the usual dose of 2 g/d[14]. Finally, if the response to MMF is inadequate, multiple salvage therapies have been described, including cyclosporine, tacrolimus, and other immunomodulatory agents (methotrexate, cyclophosphamide, rituximab, and infliximab). Nevertheless, none of the aforementioned agents have been assessed in controlled clinical trials. Therefore, evidence for third-line treatment options remains scarce, and these patients should be preferably managed in large-volume centers with sufficient expertise in AIH[6].

The treatment duration of for AIH is controversial. Considering that AIH is an idiopathic disease that develops in a background of genetic susceptibility, most patients require long-term, most likely lifelong, therapy. Only 10%-20% of patients with AIH can safely discontinue immunosuppressive therapy and maintain remission. Withdrawal of immunosuppressive agents can be attempted when a complete biochemical response has been achieved for more than two years on monotherapy, with alanine transaminase concentrations in the lower range of normal values and IgG concentrations below 12 g/L. As there is a high chance of relapse, patients with complete treatment withdrawal should be closely monitored, especially in the first six months. Late relapses can also occur decades after sustained remission, highlighting the need for lifelong surveillance in virtually all patients[13].

However, there are certain patients for whom immunosuppressive treatment is contraindicated, including cases of AIH with an acute onset and rapid progression to fulminant liver disease or patients who already have end-stage liver disease at the time of diagnosis. In both cases, liver transplantation was the only treatment option[7].

**AIH INDUCED BY HDV**

The association of HDV with positive autoantibodies and autoimmune features has been suspected for years, although it was initially suggested that hepatitis delta is directly cytopathic and that liver injury is not immunologically mediated[15]. It remains debatable whether the autoimmune features derive from previous treatment with pegylated interferon or whether HDV induces autoimmunity through molecular mimicry and bystander activation. Considerable research has been conducted on the role of HBV in inducing autoimmunity[16]. Most antibodies used for viral hepatitis are non-disease-specific or non-organ-specific (NOSA). These antibodies include ANA, anti-SMA, anti-LKM1, anti-mitochondrial antibodies, and anti-soluble liver antigen/liver-pancreas antibodies. In a recent study, Hermanussen *et al*[16] identified and analyzed three different cohorts: Forty-six patients with AIH, 42 patients with HDV, and 70 patients with HBV. They found that positive NOSA titers were more frequent in AIH than in HDV (96% *vs* 69%) but more frequent in HDV than in HBV (69% *vs* 43%). With respect to individual antibodies, ANA titers were more frequent in patients with AIH than in those with HDV (89% *vs* 76%). In addition, higher titers ≥ 1:320 were noted in 63% of patients with AIH compared with 28% in the HDV cohort. Compared to patients with HBV, ANA titers were more commonly elevated in patients with HDV co-infection (HDV 67% *vs* HBV 43%). No difference was noted in ANA titers between patients with and without detectable HDV-RNA. The same trend was observed for SMA titers, which were more frequently encountered in AIH patients than in HDV and HBV patients (AIH 50% *vs* HDV 16% *vs* HBV 3%). Patients with detectable HDV-RNA RNAtested positive more frequently, and the titers were higher than those in patients with undetectable HDVRNA. Finally, IgG levels increased in 73%, 54% of patients with HDV and 12% of patients with AIH, HDV, and HBV[16]. In addition to this study, previous reports have shown a positive correlation between pegylated interferon treatment in HBV patients and the induction of AIH in approximately 25%-40%[17]. Furthermore, isolated cases of patients with hepatitis delta have shown that AIH is also observed after treatment with pegylated interferon[18]. In contrast, a case of HDV-RNA flare has been reported in a previously negative patient who received immunosuppressive treatment for AIH[5].

**TREATMENT OF** **CHRONIC HEPATITIS DELTA**

Until recently, the management of chronic hepatitis delta (CHD) was encompassed within the HBV guidelines, as CHD was recognized as an HBV-dependent rare disease. It has even been designated an orphan disease because it affects only a small fraction of hepatitis B surface antigen (HBsAg)-positive patients. Advancements in the knowledge of HDV pathogenesis and the HDV life cycle have led to the identification of new therapeutic targets. For the first time since the discovery of HDV in the 70’s, HDV-specific antiviral agents have undergone Phase III clinical trials. Bulevirtide (BLV) was the first HDV-specific antiviral agent to receive marketing authorization from the EMA in July 2020. Owing to the complexity of CHD clinical management on the one hand and the newly available knowledge and therapeutic perspectives, the European Association for the Study of the Liver (EASL) commissioned the first international clinical practice guideline (CPG)[19] on the management of HDV-infected patients, which was first announced during the EASL meeting in June 2023.

***Pegylated Interferon a***

According to the EASL CPG2023, pegylated interferon (PegIFNα) remains a therapeutic option and is recommended for all patients with CHD and compensated liver disease, irrespective of the presence of cirrhosis, for 48 wk (LoE 2, strong recommendation, consensus)[19]. PegIFNα is associated with a decline in both HBV and HDV markers, and recent studies have shown that it significantly reduces HDV-RNA when administered in the early stages of infection[20], suggesting an inhibitory effect on viral entry and suppression of cell division-mediated HDV spread[21]. In contrast, a recent meta-analysis of 13 studies reported a virological response at 24 wk post-treatment in only 29% of patients receiving PegIFNα, and that 50% of these patients developed virological relapse later, up to 10 years after the end of treatment[22,23].

***BLV***

BLV is a synthetic myristoylated lipopeptide consisting of 47 amino acids in the preS1 domain of the HBV large surface protein that blocks the attachment of HBsAg to the cell entry receptor, NTCP[24]. It has recently been recommended for all patients with CHD and compensated liver disease (LoE 3, strong recommendation and consensus). The optimal dose and duration have not yet been established thus, until further data becomes available, long-term treatment with 2 mg BLV once daily may be considered safe and adequate (LoE 5, weak recommendation, consensus[19]. Real-world evidence from more than 500 patients treated in France, Germany, Austria, and Italy was presented at international meetings. In the French Early Access Cohort study, an increased rate of virological response from month 12 (33%) to month 24 (68%) was observed after BLV[25]. In the German real-world experience study including 114 patients BLV showed high rates of virological response (≥ 2 Log HDV-RNA decline) in 74% of patients, in a mean intervention period of 38.0 wk ± 17.6 wk. Interestingly, BLV was well tolerated without major adverse effects even in five patients with decompensated cirrhosis at baseline who achieved virological and biochemical responses[26].

***Combination treatment with BLV plus PegIFNα***

The rationale for combination therapy with BLV and PegIFNα relies on the fact that PegIFNα exhibits immunomodulatory and antiviral properties and is able to inhibit cell division-mediated HDV spread, whereas BLV inhibits HDV from entering hepatocytes, thus preventing further infection. This combination is also recommended by EASL CPG 2023 for patients without PegIFNα intolerance or contraindications (LoE 5, weak recommendation, consensus)[19], In the MYR203 study, the patients were treated for 48 wk with combination therapy. Twenty-four weeks after the end of treatment, HDVRNA was undetectable in 53% of the patients who received BLV 2 mg/d. The rates of sustained virological response were 27% and 7% in patients treated with 5 and 10 mg daily respectively[27]. In the ongoing MYR204 study, patients were randomized to receive combination treatment with BLV at a dose of 2 or 10 mg/d for 48 wk and then continued with BLV monotherapy for another 48 wk, or monotherapy with BLV at a dose of 10 mg for 96 wk. In the 24th wk of treatment, patients receiving combination therapy achieved a greater decline in HDV-RNA levels than those treated with bulevirtidine monotherapy (92% when administered PegIFNα + 10 mg BLV *vs* 88% PegIFNα + 2 mg BLV *vs* 72% in BLV 10 mg monotherapy). Although these data are promising, the number of patients was small and some points need to be clarified further[28].

***Future treatment options***

Better understanding of the HDV life cycle and its interplay with hepatocytes has enabled the development of new antiviral agents as possible candidates for CHD treatment. Besides BLV, an NTCP inhibitor, other promising agents include prenylation inhibitors that inhibit the prenylation of large HDV antigens, which are essential for HDV virion morphogenesis[29], and nucleic acid polymers, which interact with the hydrophobic surface of HBsAg and destabilize its assembly and secretion of subviral particles, leading to the degradation of intracellular HBsAg[30].

**DISCUSSION**

Over the last few decades, the interaction between viral hepatitis and autoimmune diseases has received increasing attention, with special interest in hepatitis B and D virus co-infection. In some CHD cases, clinical AIH has been reported after treatment with pegylated interferon. Starting from this observation, several questions arise, mainly concerning the exact correlation between the onset of autoimmune disease and hepatitis band D and treatment with pegylated interferon. Since all possible scenarios have been described, and many different cases have been reported in the literature, some steps have been proposed to manage AIH in patients with chronic hepatitis delta. First, all the HBsAg-positive patients were screened for HDV antibodies (anti-HDV). Consequently, HDV-RNA should be tested in all anti-HDV-positive patients, and regardless of the results, all anti-HDV-positive patients should be screened for AIH by testing serological data, suchas ANA, SMA, p-ANCA, and IgG levels, as well as transaminase levels. If serological data indicate AIH, a liver biopsy should be performed. Nevertheless, in anti-HDV-positive patients with detectable HDV-RNA levels and laboratory tests compatible with AIH, treatment with BLV should be initiated as PegIFNα is contraindicated in these cases. If a biochemical response is achieved with transaminase normalization and decreased IgG levels, treatment with BLV should still be continued. If there is a partial or no biochemical response, first-line AIH treatment with prednisolone 0.5 mg/kg of body weight/day should be considered together with BLV. First-line treatment for AIH should be applied in anti-HDV-positive patients with undetectable HDV-RNA levels, positive serological data for AIH, and elevated transaminase levels. If a biochemical response is achieved, prednisolone should be continued in a tapered manner as described previously. If there is a partial or no biochemical response, HDV-RNA should be checked, and if detectable, BLV should be initiated immediately. If it remains undetectable, second-line AIH treatment, that is, MMF, should be considered, but with great caution due to side effects. Despite a satisfactory biochemical response, all anti-HDV patients with undetectable HDVRNA who are being treated for AIH should be closely monitored for HDV reactivation by examining HDVRNA levels at least every 12-24 wk. Moreover, all patients undergoing AIH therapy should receive treatment with nucleos(t)ide analogs to avoid reactivation or exacerbation of chronic hepatitis B (Figure 1).

However, not all patients with CHD and AIH achieve biochemical and/or virological responses when treated with BLV and/or first- or second-line AIH therapy, particularly in patients with decompensated cirrhosis. In these patients, liver transplantation should be considered until new HDV anti-viral agents are available.

**CONCLUSION**

Therefore, patients with Chronic Hepatitis Delta should be evaluated for AIH. Once AIH is diagnosed, treatment with BLV should be initially administered and continued as long as there is a biochemical response. In patients with partial or no biochemical response, autoimmune therapy with prednisolone should be considered.

**REFERENCES**

1 **Rizzetto M**. Hepatitis D (DELTA). *New Microbiol* 2022; **45**: 149-154 [PMID: 35920869 DOI: 10.1055/s-0032-1323625]

2 **Taylor JM**. Infection by Hepatitis Delta Virus. *Viruses* 2020; **12** [PMID: 32560053 DOI: 10.3390/v12060648]

3 **Fattovich G**, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). *Gut* 2000; **46**: 420-426 [PMID: 10673308 DOI: 10.1136/gut.46.3.420]

4 **Alfaiate D**, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. *J Hepatol* 2020; **73**: 533-539 [PMID: 32151618 DOI: 10.1016/j.jhep.2020.02.030]

5 **Cardoso MF**, Carvalho R, Correia FP, Branco JC, Nuno Costa M, Martins A. Autoimmune hepatitis induced by hepatitis delta virus: A conundrum. *GE Port J Gastroenterol* 2023: 1-6 [DOI: 10.1159/000531773]

6 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines: Autoimmune hepatitis. *J Hepatol* 2015; **63**: 971-1004 [PMID: 26341719 DOI: 10.1016/j.jhep.2015.06.030]

7 **Muratori L**, Lohse AW, Lenzi M. Diagnosis and management of autoimmune hepatitis. *BMJ* 2023; **380**: e070201 [PMID: 36746473 DOI: 10.1136/bmj-2022-070201]

8 **Zhang X**, Jain D. The many faces and pathologic diagnostic challenges of autoimmune hepatitis. *Hum Pathol* 2023; **132**: 114-125 [PMID: 35753409 DOI: 10.1016/j.humpath.2022.06.019]

9 **Barr RG**. Shear wave liver elastography. *Abdom Radiol (NY)* 2018; **43**: 800-807 [PMID: 29116341 DOI: 10.1007/s00261-017-1375-1]

10 **Pape S**, Gevers TJG, Belias M, Mustafajev IF, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ, Hartl J, Schramm C, Lohse AW, Taubert R, Jaeckel E, Manns MP, Papp M, Stickel F, Heneghan MA, Drenth JPH. Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. *Clin Gastroenterol Hepatol* 2019; **17**: 2068-2075.e2 [PMID: 30625402 DOI: 10.1016/j.cgh.2018.12.035]

11 **Manns MP**, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, Bahr MJ, Günther R, Hultcrantz RW, Spengler U, Lohse AW, Szalay F, Färkkilä M, Pröls M, Strassburg CP; European AIH-BUC-Study Group. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. *Gastroenterology* 2010; **139**: 1198-1206 [PMID: 20600032 DOI: 10.1053/j.gastro.2010.06.046]

12 **Johnson PJ**, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. *N Engl J Med* 1995; **333**: 958-963 [PMID: 7666914 DOI: 10.1056/NEJM199510123331502]

13 **Kanzler S**, Gerken G, Löhr H, Galle PR, Meyer zum Büschenfelde KH, Lohse AW. Duration of immunosuppressive therapy in autoimmune hepatitis. *J Hepatol* 2001; **34**: 354-355 [PMID: 11281572 DOI: 10.1016/s0168-8278(00)00095-7]

14 **Hennes EM**, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, Kanzler S, Schuchmann M, Boecher W, Galle PR, Adams DH, Lohse AW. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? *Am J Gastroenterol* 2008; **103**: 3063-3070 [PMID: 18853972 DOI: 10.1111/j.1572-0241.2008.02180.x]

15 **Zauli D**, Crespi C, Bianchi FB, Craxi A, Pisi E. Autoimmunity in chronic liver disease caused by hepatitis delta virus. *J Clin Pathol* 1986; **39**: 897-899 [PMID: 3745480 DOI: 10.1136/jcp.39.8.897]

16 **Hermanussen L**, Lampalzer S, Bockmann JH, Ziegler AE, Piecha F, Dandri M, Pischke S, Haag F, Lohse AW, Lütgehetmann M, Weiler-Normann C, Zur Wiesch JS. Non-organ-specific autoantibodies with unspecific patterns are a frequent para-infectious feature of chronic hepatitis D. *Front Med (Lausanne)* 2023; **10**: 1169096 [PMID: 37387781 DOI: 10.3389/fmed.2023.1169096]

17 **Rathi C**, Pipaliya N, Choksi D, Parikh P, Ingle M, Sawant P. Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis C. *ACG Case Rep J* 2015; **2**: 247-249 [PMID: 26203454 DOI: 10.14309/crj.2015.74]

18 **Enc F**, Ulasoglu C. A case of autoimmune hepatitis following pegylated interferon treatment of chronic hepatitis delta. *North Clin Istanb* 2020; **7**: 407-410 [PMID: 33043269 DOI: 10.14744/nci.2019.47701]

19 **European Association for the Study of the Liver.** EASL Clinical Practice Guidelines on hepatitis delta virus. *J Hepatol* 2023; **79**: 433-460 [PMID: 37364791 DOI: 10.1016/j.jhep.2023.05.001]

20 **Zhang Z**, Filzmayer C, Ni Y, Sültmann H, Mutz P, Hiet MS, Vondran FWR, Bartenschlager R, Urban S. Hepatitis D virus replication is sensed by MDA5 and induces IFN-β/λ responses in hepatocytes. *J Hepatol* 2018; **69**: 25-35 [PMID: 29524530 DOI: 10.1016/j.jhep.2018.02.021]

21 **Zhang Z**, Ni Y, Lempp FA, Walter L, Mutz P, Bartenschlager R, Urban S. Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread. *J Hepatol* 2022; **77**: 957-966 [PMID: 35636579 DOI: 10.1016/j.jhep.2022.05.023]

22 **Wranke A**, Hardtke S, Heidrich B, Dalekos G, Yalçin K, Tabak F, Gürel S, Çakaloğlu Y, Akarca US, Lammert F, Häussinger D, Müller T, Wöbse M, Manns MP, Idilman R, Cornberg M, Wedemeyer H, Yurdaydin C. Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. *J Viral Hepat* 2020; **27**: 1359-1368 [PMID: 32707605 DOI: 10.1111/jvh.13366]

23 **Heidrich B**, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. *Hepatology* 2014; **60**: 87-97 [PMID: 24585488 DOI: 10.1002/hep.27102]

24 **Yan H**, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. *Elife* 2012; **1**: e00049 [PMID: 23150796 DOI: 10.7554/eLife.00049]

25 **Ledinghen V**, Hermabessiere P, Metivier S, Bardou-Jacquet E,Hilleret MN, Loustaud-Ratti V. Bulevirtide, with or without peg-interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program. 2022. [cited 12 January 2024]. Available from: https://www.natap.org/2022/AASLD/AASLD\_47.htm

26 **Dietz-Fricke C**, Tacke F, Zöllner C, Demir M, Schmidt HH, Schramm C, Willuweit K, Lange CM, Weber S, Denk G, Berg CP, Grottenthaler JM, Merle U, Olkus A, Zeuzem S, Sprinzl K, Berg T, van Bömmel F, Wiegand J, Herta T, Seufferlein T, Zizer E, Dikopoulos N, Thimme R, Neumann-Haefelin C, Galle PR, Sprinzl M, Lohse AW, Schulze Zur Wiesch J, Kempski J, Geier A, Reiter FP, Schlevogt B, Gödiker J, Hofmann WP, Buggisch P, Kahlhöfer J, Port K, Maasoumy B, Cornberg M, Wedemeyer H, Deterding K. Treating hepatitis D with bulevirtide - Real-world experience from 114 patients. *JHEP Rep* 2023; **5**: 100686 [PMID: 37025462 DOI: 10.1016/j.jhepr.2023.100686]

27 **Edemeyer H**, Schöneweis K, Bogomolov PO, Voronkova N, ChulanovV,Stepanova T, Bremer B, Allweiss L, Dandri M, Burhenne J, Haefeli W, Ciesek S, Dittmer U, Alexandrov A, Urban S. Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. *J Hepatol* 2019; **70**: e81 [DOI: 10.1016/s0618-8278(19)30141-0]

28 **Wedemeyer H**, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin IG, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp FA, Port K, Haag M, Schwab M, Zur Wiesch JS, Cornberg M, Haefeli WE, Dandri M, Alexandrov A, Urban S. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. *Lancet Infect Dis* 2023; **23**: 117-129 [PMID: 36113537 DOI: 10.1016/S1473-3099(22)00318-8]

29 **Glenn JS**, Watson JA, Havel CM, White JM. Identification of a prenylation site in delta virus large antigen. *Science* 1992; **256**: 1331-1333 [PMID: 1598578 DOI: 10.1126/science.1598578]

30 **Boulon R**, Blanchet M, Lemasson M, Vaillant A, Labonté P. Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro. *Antiviral Res* 2020; **183**: 104853 [PMID: 32585322 DOI: 10.1016/j.antiviral.2020.104853]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 7, 2023

**First decision:** December 21, 2023

**Article in press:** January 30, 2024

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Greece

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Wang K, China **S-Editor:** Chen YL **L-Editor:** A **P-Editor:** Yu HG

**Figure Legends**



**Figure 1 Management of autoimmune hepatitis induced by hepatitis delta virus.** Assess all hepatitis B surface antigen (+) patients for anti-hepatitis delta virus (HDV). For anti-HDV positive patients evaluate HDV-RNA status and autoimmune hepatitis (AIH). Consider liver biopsy for patients with serologic evidence of AIH: (1) Initiate BLV for HDV-RNA (+) and AIH (+). If there is biochemical response continue bulevirtide (BLV); If there is partial or no biochemical response use AIH targeted therapies; and (2) If HDV-RNA (-) and AIH (+) initiate treatment for AIH. If there is biochemical response continue AIH treatment; if there is partial or no biochemical response check HDV-RNA and if positive add BLV, otherwise proceed to 2nd line treatment for AIH. HDV: Hepatitis delta virus; HBV: Hepatitis B virus; AIH: Autoimmune hepatitis; ANA: Antinuclear antibodies; SMA: Smooth muscle autoantibodies; BLV: Bulevirtide; ANCA: Anti-neutrophil cytoplasmic antibodies; IgG: Immunoglobulin G; HBsAG: Hepatitis B surface antigen.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** office@baishideng.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2024 Baishideng Publishing Group Inc. All rights reserved.**